细胞周期蛋白依赖激酶6
细胞周期蛋白依赖激酶
激酶
癌变
癌症研究
细胞周期蛋白
细胞周期蛋白依赖激酶4
细胞周期
生物
癌症
乳腺癌
细胞生物学
细胞周期蛋白依赖激酶2
蛋白激酶A
遗传学
作者
Anne Fassl,Yan Geng,Piotr Siciński
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2022-01-14
卷期号:375 (6577)
被引量:122
标识
DOI:10.1126/science.abc1495
摘要
Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) and their activating partners, D-type cyclins, link the extracellular environment with the core cell cycle machinery. Constitutive activation of cyclin D–CDK4/6 represents the driving force of tumorigenesis in several cancer types. Small-molecule inhibitors of CDK4/6 have been used with great success in the treatment of hormone receptor–positive breast cancers and are in clinical trials for many other tumor types. Unexpectedly, recent work indicates that inhibition of CDK4/6 affects a wide range of cellular functions such as tumor cell metabolism and antitumor immunity. We discuss how recent advances in understanding CDK4/6 biology are opening new avenues for the future use of cyclin D–CDK4/6 inhibitors in cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI